Cargando…

Reprogramming of PD-1(+) M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma

Cutaneous T cell lymphoma (CTCL) is a disfiguring and incurable disease characterized by skin-homing malignant T cells surrounded by immune cells that promote CTCL growth through an immunosuppressive tumor microenvironment (TME). Preliminary data from our phase I clinical trial of anti–programmed ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Zhen, Wu, Xiwei, Qin, Hanjun, Yuan, Yate-Ching, Schmolze, Daniel, Su, Chingyu, Zain, Jasmine, Moyal, Lilach, Hodak, Emmilia, Sanchez, James F., Lee, Peter P., Feng, Mingye, Rosen, Steven T., Querfeld, Christiane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371344/ https://www.ncbi.nlm.nih.gov/pubmed/37427589 http://dx.doi.org/10.1172/jci.insight.163518

Ejemplares similares

Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides
por: Di Raimondo, Cosimo, et al.
Publicado: (2021)

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders
por: Abdulla, Farah R., et al.
Publicado: (2021)

Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data
por: Querfeld, Christiane, et al.
Publicado: (2022)

Stage-dependent Increase in Expression of miR-155 and Ki-67 and Number of Tumour-associated Inflammatory Cells in Folliculotropic Mycosis Fungoides
por: ATZMONY, Lihi, et al.
Publicado: (2020)

Effects of PD-1 Signaling on Immunometabolic Reprogramming
por: Boussiotis, Vassiliki A., et al.
Publicado: (2022)

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
por: Giuliani, Massimo, et al.
Publicado: (2017)

Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1
por: Cai, Hao, et al.
Publicado: (2021)

Expression of immune checkpoint molecules programmed death protein 1, programmed death‐ligand 1 and inducible T‐cell co‐stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome
por: Di Raimondo, Cosimo, et al.
Publicado: (2022)

Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo
por: Mazuz, Moran, et al.
Publicado: (2020)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
por: Király, Zsófia, et al.
Publicado: (2022)

Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
por: Trum, Nicholas A., et al.
Publicado: (2021)

Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience
por: Geskin, Larisa J., et al.
Publicado: (2021)

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
por: Laubach, Kyra, et al.
Publicado: (2023)

Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
por: Hodak, Emmilia, et al.
Publicado: (2022)

Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
por: Hodak, Emmilia, et al.
Publicado: (2023)

mAb14, a Monoclonal Antibody against Cell Surface PCNA: A Potential Tool for Sezary Syndrome Diagnosis and Targeted Immunotherapy
por: Knaneh, Jamal, et al.
Publicado: (2023)

The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin
por: Moyal, Lilach, et al.
Publicado: (2016)

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
por: Noman, Muhammad Zaeem, et al.
Publicado: (2020)

Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment
por: Paolini, Léa, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
por: Mukherjee, Debayan, et al.
Publicado: (2023)

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
por: Zhao, Mingye, et al.
Publicado: (2022)

Cutaneous metastasis of PD-L1 positive ovarian carcinoma
por: Hastings, Victoria, et al.
Publicado: (2020)

Cutaneous metastasis of PD-L1 positive cervical carcinoma
por: Liu, Chrissy, et al.
Publicado: (2022)

PD-L1 Activity Is Associated with Partial EMT and Metabolic Reprogramming in Carcinomas
por: Muralidharan, Srinath, et al.
Publicado: (2022)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
por: Babačić, Haris, et al.
Publicado: (2020)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
por: Gao, Yumei, et al.
Publicado: (2023)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

PD-1/PD-L1 Control of Antigen-Specifically Activated CD4 T-Cells of Neonates
por: Majer, Christiane, et al.
Publicado: (2023)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b9gq5jj1n80j2n7rphoibksuqq